ICICI Pru Nifty Pharma Index Fund(IDCW)
Ticker: mf17398
Decent
68/100
☆ Add to Watchlist
More Options
A
Aditya Birla SL US Treasury 1-3 year Bond ETFs FoF(IDCW Reinvest)
The fund is a conservative investment with low growth potential, suitable for risk-averse investors.
View details
A
Aditya Birla SL US Treasury 1-3 year Bond ETFs FoF(IDCW)
The fund shows moderate potential with stable returns but lacks strong growth catalysts.
View details
K
Kotak International REIT Overseas Equity Omni FOF(IDCW)
The fund shows several weaknesses in growth and profitability metrics, indicating a risky investment at this time.
View details
K
Kotak International REIT Overseas Equity Omni FOF(IDCW Payout)
The fund shows potential for moderate growth, but investors should be cautious due to execution risks and valuation concerns.
View details
L
LIC MF Healthcare Fund(IDCW)
The LIC MF Healthcare Fund shows decent potential with strong growth and profitability metrics, but some execution risks need to be monitored.
View details
P
PGIM India Corp Bond Fund(M-IDCW)
The fund shows decent stability but lacks strong growth drivers. Investors should be cautious.
View details
P
PGIM India Corp Bond Fund(Q-IDCW)
The fund shows decent potential but is hindered by inconsistent growth and average profitability metrics.
View details
P
PGIM India Corp Bond Fund(A-IDCW)
The fund shows decent potential but is facing challenges in profitability and growth drivers.
View details
T
Tata Nifty Auto Index Fund(IDCW Payout)
The Tata Nifty Auto Index Fund shows decent potential but faces challenges in profitability and valuation. Investors should be cautious and monitor market developments closely.
View details
T
Tata Nifty Auto Index Fund(IDCW)
The Tata Nifty Auto Index Fund shows potential with a decent score, but investors should be cautious of market volatility and execution risks.
View details
L
LIC MF BSE Sensex Index Fund(IDCW)
The LIC MF BSE Sensex Index Fund shows decent potential with a diversified portfolio and consistent growth, but investors should be cautious of valuation and governance aspects.
View details
3
360 ONE ELSS Tax Saver Nifty 50 Index Fund(IDCW)
The fund shows a decent investment opportunity with stable growth and profitability metrics, though some risks remain due to market conditions.
View details
D
DSP Nifty SDL Plus G-Sec Sep 2027 50:50 Index Fund(IDCW)
The fund offers stability but lacks significant growth potential, making it a risky investment for aggressive investors.
View details
S
SBI FMP-79-1130D(IDCW)
The stock presents a decent investment opportunity but with notable risks and limited growth potential.
View details
M
Mirae Asset Nifty AAA PSU Bond Plus SDL Apr 2026 50:50 Index Fund(IDCW)
The fund shows moderate potential but is hindered by inconsistent profitability and limited growth drivers.
View details
I
ICICI Pru Retirement Fund-Hybrid Cons Plan(IDCW)
The ICICI Pru Retirement Fund-Hybrid Cons Plan shows decent potential with a stable growth outlook, but investors should be cautious of execution risks.
View details
Business Overview
ICICI Pru Nifty Pharma Index Fund (IDCW) is a mutual fund that aims to replicate the performance of the Nifty Pharma Index, providing investors with exposure to the Indian pharmaceutical sector. Ideal for those looking to diversify their portfolio with a focus on healthcare, this fund captures the growth potential of leading pharma companies. It offers a systematic approach to investing, making it suitable for both new and seasoned investors seeking long-term gains in a thriving industry.
- Diversified exposure to top pharmaceutical companies
- Ideal for long-term wealth creation
- Low expense ratio compared to actively managed funds
- Systematic Investment Plan (SIP) options available
- Managed by experienced professionals
- Aligned with India's growing healthcare sector
Investment Thesis
ICICI Pru Nifty Pharma Index Fund (IDCW) stands out due to its strong backing from the reputable ICICI Group, ensuring credibility and trust. The fund is positioned to benefit from the robust growth of digital services in the pharma sector, offering a promising growth runway. Additionally, its attractive valuation compared to peers makes it a compelling investment choice for retail investors.
- Strong promoter group enhances credibility and investor confidence.
- Significant growth potential in digital services within the pharma sector.
- Attractive valuation compared to other pharma-focused funds.
- Diversified exposure to leading pharma companies through the index.
- Aligned with India's increasing healthcare spending and innovation.
Opportunity vs Risk
Opportunities
- Growing pharmaceutical sector in India
- Increased healthcare spending
- Government support for pharma
- Diversification through index fund
- Potential for long-term capital gains
Risks ⚠️
- Market volatility in pharma stocks
- Regulatory changes impact
- Global supply chain disruptions
- High competition in sector
- Economic downturn affecting spending
Peer Perspective
ICICI Pru Nifty Pharma Index Fund trades at a slight premium compared to peers like Nippon India Pharma ETF and SBI Nifty Pharma ETF. A sustained improvement in margin stability could trigger a rerating.
📊 Stock Investment Checklist (100 Points)
ICICI Pru Nifty Pharma Index Fund(IDCW) • Updated: 2025-10-01 06:16:45
-
10BusinessHighPharma sector has growth potential but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth observed in the pharma sector.
-
10ProfitabilityHighROE and OCF are stable but not exceptional.
-
8ValuationHighValuation metrics are in line with industry averages.
-
7BalanceHighDebt levels are manageable, liquidity is adequate.
-
6GovernanceGoodPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are notable.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
The fund is positioned well within the pharma sector, showing decent growth potential but with some risks involved.